AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01377961 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks
Description: After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.~The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks.
Study NCT01377961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
Study NCT01377961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OGTT
Description: OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
Study NCT01377961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anthropometrics and Blood pressure
Description: Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
Study NCT01377961 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Drawing
Description: The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
Study NCT02589769 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: unsaturated fat for saturated fat
Description: Substituting unsaturated fat for saturated fat
Study NCT02589769 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: saturated fat
Description: a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
Study NCT04706871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the cymba conchae and concha around the left ear.
Study NCT04706871 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: tnVNS
Description: tnVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 30 Hz with pulse duration ≤ 1 ms, for 30min, administered twice daily.~The two electrodes were placed on the antihelix around the left ear.
Study NCT04651023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nelumbo nucifera Leaf Extract
Description: Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
Study NCT02957786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: Cytisine tablets
Study NCT02957786 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural support
Description: Withdrawal-orientated cessation support
Study NCT02957786 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioural support
Description: Withdrawal-orientated cessation support
Study NCT02957786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline tablets
Study NCT03255031 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketogenic Diet (KD)
Description: For each meal at breakfast, lunch and dinner, the diets will consist of ketogenic diet (KD) meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
Study NCT03255031 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard American (SA) Meals and Shakes
Description: For each meal at breakfast, lunch and dinner, the diets will consist of SA meal (carbohydrate rich) KD meal. Compliance tests are done twice a week with a blood test measuring ketone levels.
Study NCT02033876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodiol
Study NCT02033876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol
Study NCT02490566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
Study NCT03667625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional Mobility Exercises
Description: Multidimensional mobility exercises, combined with breathing exercise protocol was established by a committee of specialized physiotherapists and rheumatologist. Land-based and aquatic-based exercises were designed according to environmental features (gravity, buoyancy, viscosity etc).
Study NCT03667625 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A conventional home exercise programme was given by a specialized physiotherapist to control group. Patients were checked and encouraged to continue their programs by weekly phone calls for eight weeks
Study NCT01596816 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: First part of treatment : Conformal irradiation
Description: 23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
Study NCT01596816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiducials placement
Description: Placement of intra-prostatic markers for the tracking
Study NCT03594786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endovascular aneurysm repair (EVAR)
Description: Patient will be enrolled when the decision of an endovascular procedure with supra renal fixation is required. Before the intervention, Duplex scan will be necessary to evaluate renal arteries ostia. This exam will be realised in the month after the intervention and one year later.
Study NCT06311448 — intervention group
Intervention type: DRUG
Intervention: Single target immunomodulation
Description: Single target immunomodulation compromise of drugs which very specifically target cytokines, chemokines or specific receptors, which are involved in the pathofysiology of COVID-19. For instance, tociluzimab (IL-6 receptor blocker), Anakinra (IL-1 receptor blocker), Eculizimab (Complement inhibitor C5), etc.
Study NCT06311448 — intervention group
Intervention type: DRUG
Intervention: Standard of care
Description: Standard of care during COVID-19 pandemic including steroids.
Study NCT01596816 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Second part : hypofractionated stereotactic boost
Description: 3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
Study NCT02140073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omeprazole+domperidone SR
Description: omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
Study NCT02140073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: 40mg in the morning
Study NCT01652118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia
Study NCT01652118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT03716505 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore Sapphire active
Description: GammaCore Sapphire™ is a handheld, non-invasive, low voltage electrical device which stimulates the vagus nerve by producing weak 120 second electrical stimulation cycles that may help reduce, ease, lessen or stop your migraine symptoms. GammaCore Sapphire™ has been approved for the treatment of headache, including migraine by the United States Food and Drug Administration (FDA).
Study NCT03716505 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: gammaCore Sapphire Sham
Description: The sham device is a hand-held portable device that appears identical to gammaCore Sapphire, in look, weight, visual and audible feedback, user application, and control. Like gammaCore Sapphire, the sham device is a multi-use device.
Study NCT04429373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant installation with PRF membrane
Description: Platelet-rich fibrin membrane over the buccal aspect of implant site after dental implant installation
Study NCT04429373 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant installation without PRF membrane
Description: Implant installation contralateral to the experimental side without PRF membrane
Study NCT04651023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nelumbo nucifera Leaf Extract
Description: Hot water extracted Nelumbo nucifera Leaf, mainly containing quercetin and quercetin 3-O-glucuronide.
Study NCT03943732 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FilmArray Pneumonia
Description: FilmArray Pneumonia testing of tracheal sample
Study NCT01477034 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
Study NCT02730039 — intervention group
Intervention type: BEHAVIORAL
Intervention: workshop
Study NCT02730039 — intervention group
Intervention type: BEHAVIORAL
Intervention: follow-up calls & webinars
Study NCT02730039 — intervention group
Intervention type: BEHAVIORAL
Intervention: assessments
Study NCT01126593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Description: Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
Study NCT01126593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
Study NCT04624269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
Study NCT04624269 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Hydroxychloroquine Sulfate Tablets ,0.1mg，bid po
Study NCT03242382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
Study NCT02460874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: 1.25mg, twice a day
Study NCT02460874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glyburide
Description: 1.25mg, twice a day
Study NCT02460874 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.25mg, twice a day
Study NCT03016663 — intervention group
Intervention type: PROCEDURE
Intervention: Technique of Breast Lipofilling
Description: 1. Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.~2. Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.~   Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).~3. Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.~4. Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided.
Study NCT01873638 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cholecystectomy
Study NCT01591031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
Study NCT01591031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
Study NCT02191956 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Parent Training
Description: Weekly clinic session, mid-week call, home practice
Study NCT02191956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Weekly clinic session, mid-week call, home practice
Study NCT03151499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Reference and Test Treatment
Study NCT03151499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Test Treatment
Study NCT00856778 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Virtue® Male Incontinence Sling
Description: The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
Study NCT00938600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 oral liquid 70,000 IU once
Study NCT00938600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
Study NCT00938600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
Study NCT01956682 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HA formula + starch + L. reuteri
Study NCT00615771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Day 3 embryo transfer
Description: Standard of care
Study NCT00615771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Description: Embryos are transferred 1 day prior to standard of care
Study NCT00971672 — intervention group
Intervention type: OTHER
Intervention: Questionnaire filling and laboratory analysis
Description: A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.~The laboratory analysis will include complete blood count and serum ferritin analysis.
Study NCT03671265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
Study NCT03671265 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT or VMAT
Description: The IMRT or VMAT technique was used in our study.
Study NCT03671265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2.
Study NCT04160949 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study NCT03812068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long-distance developmental behavioral intervention
Description: Long-distance learning program combined parent-mediated developmental behavioral intervention
Study NCT03812068 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Developmental behavioral intervention
Description: Parent-mediated developmental behavioral intervention
Study NCT02371967 — intervention group
Intervention type: DRUG
Intervention: Vismodegib
Description: Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
Study NCT00355069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic (computer based) provider feedback tool
Description: All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
Study NCT00355069 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: electronic (computer based) provider feedback tool
Description: All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
Study NCT00845754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketorolac
Description: 15mg IV every6 hours for 4doses
Study NCT00845754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: 15mg IV every 6hrs for 4 doses
Study NCT03057119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educational content (5 Minutes)
Description: The interventionist will discuss substance use and misuse and the influence of substance use on self care.
Study NCT03057119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Readiness Assessment (10 minutes)
Description: The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
Study NCT00769899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: Capsule for oral, single dose
Study NCT00769899 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule for oral, single dose
Study NCT02115685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill Training
Description: Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
Study NCT01403454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Health Communication Application
Description: web-based application
Study NCT01605461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 NA
Description: Single oral solution dose of BI 207127 NA combined with \[14C\]-BI 207127 NA
Study NCT01294878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
Study NCT00446654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CGC-11047
Description: 16.5 mg (3.3%) subconjunctival injection
Study NCT03618966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular magnetic stimulation (NMMS)
Description: It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
Study NCT03618966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular magnetic stimulation (NMMS)
Description: It is a non-invasive, stimulation technique that does not induce high-intensity cutaneous electric fields and does not activate skin nociceptors, thus resulting in a painless and better-tolerated procedure. rNMMS is delivered through a high-frequency magnetic stimulator connected to a conventional circular cooled coil. Magnetic stimulator is placed above the flexor muscles of the forearm. rNMMS is delivered at a 5-Hz frequency and with a 100% stimulation intensity of 100% of the maximum intensity in 140 trains of 50 stimuli. sNMMS is delivered with a sham coil producing similar acoustic sensations and mechanical skin perceptions.
Study NCT01797419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-5806
Description: Single dose, oral liquid, .5 mL/kg
Study NCT01797419 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, oral liquid, .5 mL/kg
Study NCT03154333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diacerein 1% ointment
Description: diacerein 1% ointment administered topically
Study NCT03154333 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A placebo ointment
Description: vehicle ointment administered topically